Expert Ratings for Royalty Pharma
Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings:
Royalty Pharma: Q2 Earnings Insights
Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
Theravance Biopharma, Inc. (NASDAQ:TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic…
Theravance Biopharma To Sell TRELEGY ELLIPTA Royalty Interests To Royalty Pharma for ~$1.1B In Upfront Cash With Over $1.5B In Potential Total Value
Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV
Management of Technology Companies Continue Selling – Zillow (Z)
In a week where we saw most market indices rebound sharply, insiders scaled back their buying after three weeks of elevated buying. Buying declined by 64% in absolute dollar terms and 26% in terms of the number of companies that saw insider buying.
Royalty Pharma Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters.
Expert Ratings for Royalty Pharma
Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter:
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.